Treatment with oral VEGFR-TKIs may carry an increased risk of aneurysm and artery dissection. Tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR-TKIs) are ...

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled, ...

A 65-year-old man presented with episodes of fainting. Assessment showed his symptoms were related to compression of the superior vena cava from extensive swelling of the supraclavicular, mediastinal, ...

Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). Background: Several small molecule tyrosine kinase inhibitors (TKI) targeting ...

Preoperative VEGFR-TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment ...

Please provide your email address to receive an email when new articles are posted on . The use of vascular endothelial growth factor receptor tyrosine kinase inhibitors significantly increased the ...

Treatment with a vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFR–TKI) after previous treatment with checkpoint-inhibitor therapy alone or in combination with a VEGFR–TKI ...

Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth.

Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells. Evaluation of the combined expression of chemokine SDF-1α and its receptor CXCR4 as a marker for prognosis in gastric ...

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...

Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, ...